FREE SHIPPING TO U.S. AND PUERTO RICO FOR ALL ORDERS $100 AND OVER!

We are unable to accept returns on any products or test kits. All sales are final.

FREE SHIPPING TO U.S. AND PUERTO RICO FOR ALL ORDERS $100 AND OVER!

We do not currently ship internationally.

SKU: hse1308 Product Categories: , Health Conditions: ,

Cyrex Array 2 Intestinal Permeability Screen

Leaky Gut Test Cyrex Array 2
Increased permeability of the intestinal barrier to macromolecules is associated with a variety of local and systemic inflammatory conditions. Intestinal
permeability can cause systemic inflammation,which can then sustain itself by its ongoing effect on the gut.
The target tissue damage is primarily determined by genetics and exposure of environmental factors,leading to various clinical conditions including:
Gluten Sensitivity and Celiac disease
Food Allergies
Inflammatory bowel disease (Ulcerative Colitis and Crohn’s disease)
Numerous autoimmune diseases (Rheumatoid Arthritis, Psoriasis, Type 1 Diabetes,Spondylitis, etc.)
Neurological conditions (Multiple Sclerosis, Guillain Barré Syndrome, etc.)
Cognitive Dysfunction (depression, anxiety, Schizophrenia, etc.)
Others
Ready to find out if you have leaky gut?
  • Purchase on our secure website.
  • Lab order is provided by us.
  • You receive a collection kit for a blood draw at a local lab or mobile draw at your home. Draw fee may apply.
  • You receive the results by email within 2-3 weeks.
  • Practitioner phone consultations available for an additional fee.

$329.00

Patient Name

The patient's name is required for all test kit purchases

Date of Birth

The patient's Date of Birth is required for all test kit purchases

Patient's Gender

The patient's gender is required for all test kit purchases

Subtotal:

Add-ons total:

Total:

Description

Intestinal Antigenic Permeability Screen Requires a blood draw.

Elevated antibodies to LPS, Occludin/Zonulin and the Actomyosin Network are patent pending biomarkers that identify the breakdown of a healthy in
testinal barrier, which allow penetration of largeantigenic molecules:
1.Lipopolysaccharides (LPS) are large molecules found in gram-negative bacteria. They are endotoxins, and if absorbed, elicit a strong immune response.The detection of antibodies against LPS reveals macromolecule-sized endotoxin infiltration through the intestinal barrier into the systemic circulation.
2.Occludin is part of the main component of proteins holding together the tight junctions. The detection of antibodies to occludin indicates that the tight junctions are breaking down. This is a measure of a mechanism involved in dama ging the intestinal barrier membrane.
3.Zonulin, a protein, regulates the permeability of the intestine. The detection of antibodies against zonulin indicates that the normal regulation of tight junctions is compromised. This can be a clue to presence of an ongoing mechanism involved in damaging the intestinal barrier.
4.The Actomyosin Network, a protein complex, regulates intestinal barrier function by maintaining the plasticity of tight junctions.
Antibodies to the actomyosin network are a biomarker of intestinal barrier dysregulation via cell infiltration. For example, 98.2% of Celiac disease patients
with flat mucosa have antibodies to actin.This is a measure of mechanism involved in damaging the intestinal barrier.
Actomyosin IgA ( CPT CODE : 86256 )
Occludin/Zonulin IgG ( CPT CODE : 86256-59 )
Occludin/Zonulin IgA ( CPT CODE : 86256-59 )
Occludin/Zonulin IgM ( CPT CODE : 86256-59 )
Lipopolysaccharides (LPS) IgG ( CPT CODE : 86256-59 )
Lipopolysaccharides (LPS) IgA ( CPT CODE : 86256-59 )
Lipopolysaccharides (LPS) IgM ( CPT CODE : 86256-59 )

Brand

Cyrex Labs

Cyrex Labs is an advanced clinical laboratory focusing on mucosal, cellular and humoral immunology and specializing in antibody arrays for complex thyroid, gluten and other food-associated autoimmunities and related neurodysregulation. Cyrex’s Scientific Advisory Board, comprised of experts from a variety of medical and research disciplines, brings together the latest findings from medical research and the assessment needs of today’s healthcare professionals. Out of this collaboration, Cyrex develops the next generation of clinical lab testing that is required to care for present-day complex maladies.

Cyrex adheres to and surpasses the highest standards of clinical laboratory testing worldwide. A Cyrex-designed quality control criterion called The Double Assurance System (QC2™) is the standard operating procedure at Cyrex Laboratories. In fact, Cyrex’s proprietary QC2™ method enhances the reproducibility, specificity and sensitivity of all Cyrex arrays. Only Cyrex tests contain the accuracy enhancements provided by The Double Assurance System.

Before ordering please consider the following: • Patient has been clear of immunosuppressant AND/OR corticosteroid drugs for at least 60 days. • Patient has had timely and adequate antigen exposure in order to measure antibody responses.

Q: Are there any medications, foods, conditions or other factors that could interfere with the results of a Cyrex test?

A: Yes. While Cyrex is unable to provide an exhaustive answer to this question due to the interactive complexities and varieties of medications and patient circumstances, the following has been noted:

a. Immunosuppressant and corticosteroid drugs can reduce antibody production and cause false negative results. b. Limited assessments on the effects of aspirin, acetaminophen, and antipsychotics on Arrays 1-4 have been performed. No noticeable effects were observed. c. Inhalers can affect the results of Cyrex's oral fluid testing (Array 1). Wait two weeks after completion of inhalant dosages before collecting the specimen. d. Unknown cross-reactive epitopes from foods and microorganisms may stimulate the antibody production in the absence of a true antigen. Cyrex has already developed Array 4 in order to recognize the most common antigens in this regard. e. A gluten-free diet can cause false negative results on gluten protein/peptide tests. f. Certain conditions, such as ileal pouch surgery, may cause a false positive celiac serology.1

1. Lian L, Remzi FH, Kiran RP, Fazio VW, Shen B. Clinical implication of false-positive celiac serology in patients with ileal pouch. Dis Colon Rectum. 2010 Oct; 53(10):1446-1451.
Cyrex Labs
Open Lock Icon
Login to your account